VSee Health Selected for NIH-Funded Phase 3 Stroke Telerehabilitation Trial Across 29 Hospitals
核心洞察
VSee Health (搜索) has been selected to support a NIH-funded Phase 3 clinical trial evaluating gamified, home-based telerehabilitation for stroke (搜索) recovery across 29 hospitals and 202 patients.
The trial will assess 6 weeks of telerehab interventions to improve arm functionality in stroke (搜索) survivors while reducing transportation costs, caregiver burdens, and hospital readmissions.
Success in this Phase 3 trial could open doors for Medicare and private payer reimbursement in the $328 million global stroke (搜索) rehabilitation market.
VSee Health (搜索), Inc. (Nasdaq: VSEE) has been selected to support a NIH-funded Phase 3 clinical trial investigating stroke (搜索) recovery telerehabilitation, marking a significant milestone in digital health innovation for neurological rehabilitation. The UCLA-based trial represents the second such national study of post-stroke telerehabilitation and spans 29 hospitals with 202 patients enrolled.
Trial Design and Objectives
The Phase 3 study will evaluate the outcomes of adding 6 weeks of gamified, home-based telerehabilitation to improve arm functionality in stroke (搜索) survivors. The intervention aims to reduce multiple healthcare burdens including transportation costs, caregiver responsibilities, and hospital readmissions. Enrollment is scheduled to begin in Q3 2025, with the study combining independent and remote therapist-supervised games and exercises delivered through VSee's platform.
According to Dr. Steven Cramer, MD, Professor of neurology at UCLA and co-principal investigator, "Reaching Phase 3 in a clinical trial of this scale is a hard-won milestone that has been twelve years in the making—one that wouldn't have been possible without the right partners. VSee Health (搜索)'s HIPAA-compliant platform has been instrumental in ensuring secure, seamless delivery of our interventions—critical for maintaining compliance and engagement in a large-scale trial like this."
Market Implications and Reimbursement Potential
The proven efficacy demonstrated in Phase 3 trials opens significant opportunities for Medicare and private payer reimbursement within the $328 million global stroke (搜索) rehabilitation market. The telehealth approach has the potential to disrupt traditional physical therapy models by offering better patient adherence and lower costs compared to conventional in-person treatments.
Dr. Milton Chen, PhD, Co-CEO of VSee Health (搜索), emphasized the broader implications: "We're grateful and proud of VSee's role in two of the only nationwide U.S. stroke (搜索) tele-rehab trials. This Phase 3 trial validates telehealth as a scalable, cost-effective model for neurorehabilitation, and positions VSee as the go-to platform for the next wave of value-based virtual care that improves outcomes while reducing costs."
Addressing Healthcare Access Barriers
The trial specifically targets key barriers in stroke (搜索) rehabilitation, including limited access to physical therapy clinics and poor patient motivation. By utilizing gamified interventions delivered through VSee's HIPAA-compliant platform, the study aims to overcome these traditional obstacles to effective rehabilitation.
Expansion Potential Beyond Stroke
Success in this stroke (搜索) rehabilitation trial could pave the way for gamified telerehabilitation applications in other neurological conditions, including multiple sclerosis (搜索), spinal cord injury (搜索), and traumatic brain injury (搜索) rehabilitation. This expansion potential represents a significant opportunity for digital health platforms in the broader neurorehabilitation market.
VSee Health (搜索)'s involvement in this Phase 3 trial builds on the company's previous participation in Phase 1 and Phase 2 studies of this neurology research program, further solidifying its position as a key player in the telerehabilitation market.